Aug 15
Opportunity
The experience of patients participating in clinical trials may not consistently meet expectations. Poor participant experience is a negative influencer of recruitment, retention, and reputation. Therefore, it is important to provide clinical trial participants with the opportunity to provide feedback on various aspects of the study (including the study information, assessments, visit type / schedule, devices, the site and impact on their time) to improve participant experience on current and future studies.
Considerations to Help Action the Opportunity
- Define the factors that impact patient experience during a trial. Factors may include quality of care (e.g., treatment, inclusion / exclusion criteria), ease and convenience (e.g., site / location, travel, reimbursement), connection and human touch (e.g., communication, information, site staff)
- Understand which tools can be utilized to collect participant feedback and measure these patient experience factors. This could include both qualitative methods, like in trial or exit interview, or quantitative participant feedback questionnaires (e.g., optional surveys) administered at different timepoints on the study. Understand whether these tools cover all countries of interest (where the sponsor is allowed to operate)
- Utilize standardized participant feedback tactics to help elicit actionable participant feedback to potentially reduce patient burden
- Consult clinical sites early for their input into standardized participant feedback tactics to better enable rapid identification of actionable participant insights and facilitated implementation of mitigation actions at site level
- Standardize the collection of participant feedback within the organization, to enable cross-study aggregation of data for identification of significant insights not possible at an individual study level (e.g., identify specific patient populations with low patient experience)
- Clearly define how to analyze, visualize and interpret patient experience data
- Provide study teams access to the data in real-time to better enable actionable insights at study and site level
- Provide sites with aggregated (anonymized) learnings to better enable them to take actions to potentially improve patient experience at their site
- Provide patients with aggregated (anonymized) feedback and actions taken to demonstrate to them the value of providing feedback and help motivate further engagement with clinical trials
- Embed the process to collect, analyze and interpret patient experience feedback into existing processes to help limit burden on study team
Value and Potential Benefits
- Provides study teams with actionable feedback so they can take steps to reduce burden on current and future studies to potentially improve the patient’s experience in clinical studies
- Increases patient adherence and compliance to clinical study procedures, which consequently improves the data quality
- Increases trust and engagement through better communication and participation in feedback processes
- Potentially increases recruitment into trials and reduces study participant dropout rates
Related Blog Posts
Solving the Clinical Trial Data Problem
In a new LinkedIn article, Janice Chang, CEO of TransCelerate, and Nicholas Brooke, CEO of The Synergist & PFMD, outline how efforts like the Clinical Trial Data Network, supported by TransCelerate through technical expertise and industry-vetted solutions from our Digital Data Flow initiative, aim to make clinical trial information more structured, connected, and accessible across…
The Clinical Trial Enterprise: Can AI Fix It?
Artificial Intelligence (AI) is reasonably well established in discovery and preclinical research, with success in areas such as target identification and molecular modeling. However, in clinical development, adoption has been fragmented and challenging to embed across the lifecycle. Read the full article by Rob DiCicco from Drug Discovery News here.
Redesigning Clinical Trials Using Artificial Intelligence
While tech evangelists often tout artificial intelligence (AI) as healthcare’s silver bullet, the reality in clinical trials is more complex. Adoption has been cautious, shaped as much by concerns around trust and governance as by technical hurdles. Still, beneath the surface, methodical innovation is gaining momentum. AI is beginning to reshape how trials are designed,…